Medical Devices and Technologies
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities.
Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.
Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.
For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.
Our clients in the medical devices sector include Biomet, Samsung, GE Healthcare, Johnson & Johnson, Fresenius, Covidien, St Jude Medical and Novartis.
News & insights
News: 10 JULY 2020
Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…Read more
Publications: 08 JULY 2020
Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.Read more
Publications: 24 JUNE 2020
Our life sciences sector team reviews the steps taken by the industry and public bodies to minimise disruption to regular business activities and to promote the development and supply of medicines and…Read more
Publications: 24 JUNE 2020
On 21 June the UK Government announced plans to introduce a new public interest consideration to the UK merger control regime: public health emergency. It also announced a proposal to expand its…Read more